MUCINOUS ADENOCARCINOMA
Clinical trials for MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to outsmart stubborn colorectal cancer
Disease control OngoingThis phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC